Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Catalyst Pharmaceuticals, Inc is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Pharmaceuticals employs 76 staff and has a trailing 12-month revenue of around USD$118.2 million.
|Latest market close||USD$3.18|
|52-week range||USD$2.55 - USD$5.28|
|50-day moving average||USD$3.543|
|200-day moving average||USD$3.6085|
|Wall St. target price||USD$7.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.67|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-8.88%|
|1 month (2020-12-23)||-7.02%|
|3 months (2020-10-23)||-0.31%|
|6 months (2020-07-23)||-33.33%|
|1 year (2020-01-23)||-24.29%|
|2 years (2019-01-23)||29.80%|
|3 years (2018-01-23)||3.55|
|5 years (2016-01-22)||51.43%|
Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Catalyst Pharmaceuticals shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$40.8 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$118.2 million|
|Operating margin TTM||34.43%|
|Gross profit TTM||USD$87.5 million|
|Return on assets TTM||18.73%|
|Return on equity TTM||60.93%|
|Market capitalisation||USD$387.6 million|
TTM: trailing 12 months
There are currently 10.2 million Catalyst Pharmaceuticals shares held short by investors – that's known as Catalyst Pharmaceuticals's "short interest". This figure is 17.3% down from 12.3 million last month.
There are a few different ways that this level of interest in shorting Catalyst Pharmaceuticals shares can be evaluated.
Catalyst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catalyst Pharmaceuticals shares currently shorted divided by the average quantity of Catalyst Pharmaceuticals shares traded daily (recently around 2.0 million). Catalyst Pharmaceuticals's SIR currently stands at 5.02. In other words for every 100,000 Catalyst Pharmaceuticals shares traded daily on the market, roughly 5020 shares are currently held short.
However Catalyst Pharmaceuticals's short interest can also be evaluated against the total number of Catalyst Pharmaceuticals shares, or, against the total number of tradable Catalyst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Catalyst Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1054% of the tradable shares (for every 100,000 tradable Catalyst Pharmaceuticals shares, roughly 105 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Pharmaceuticals.
Find out more about how you can short Catalyst Pharmaceuticals stock.
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $2.55 up to $5.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.5305. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.